ENTERA BIO LTD. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
ENTERA BIO LTD. (ENTX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$17.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-07
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$15.00K, a 148.39% decline year-over-year.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.00K, a 100.23% decline year-over-year.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $204.00K, a 34.62% decline year-over-year.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$77.00K.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $1.04M, a 414.29% increase from fiscal 2024.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $203.00K.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$563.00K.
- ENTERA BIO LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$1.57M, a 206.59% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$17.00K 10-Q · filed 2026-08-07 | $187.00K derived: sum of 3 quarters · filed 2026-08-07 | $110.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$2.00K 10-Q · filed 2026-05-08 | $202.00K derived: sum of 2 quarters · filed 2026-05-08 | $125.00K derived: sum of 3 quarters · filed 2026-05-08 | $156.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $127.00K derived: sum of 2 quarters · filed 2026-03-27 | $158.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.04M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$46.00K derived: sum of 2 quarters · filed 2026-08-07 | $840.00K 10-Q · filed 2025-11-14 | $1.15M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $917.00K 10-Q · filed 2026-08-07 | $1.23M derived: sum of 3 quarters · filed 2026-08-07 | $924.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $886.00K 10-Q · filed 2026-05-08 | $1.20M derived: sum of 2 quarters · filed 2026-05-08 | $893.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.06M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $7.00K derived: sum of 2 quarters · filed 2026-03-27 | $175.00K derived: sum of 3 quarters · filed 2026-03-27 | $203.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$137.00K derived: sum of 2 quarters · filed 2025-11-14 | -$109.00K 10-Q · filed 2025-11-14 | -$771.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $196.00K 10-Q · filed 2025-08-08 | -$466.00K derived: sum of 3 quarters · filed 2025-08-08 | -$619.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $28.00K 10-Q · filed 2025-05-09 | -$634.00K derived: sum of 2 quarters · filed 2025-05-09 | -$787.00K derived: sum of 3 quarters · filed 2025-05-09 | -$598.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$662.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$815.00K derived: sum of 2 quarters · filed 2025-03-28 | -$626.00K derived: sum of 3 quarters · filed 2025-03-28 | -$563.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | -$153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $36.00K derived: sum of 2 quarters · filed 2024-11-08 | $99.00K 10-Q · filed 2024-11-08 | $680.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $252.00K 10-Q · filed 2024-08-09 | $833.00K derived: sum of 3 quarters · filed 2024-08-09 | $74.00K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $63.00K 10-Q · filed 2024-05-10 | $644.00K derived: sum of 2 quarters · filed 2024-05-10 | -$115.00K derived: sum of 3 quarters · filed 2024-05-10 | -$697.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$178.00K derived: sum of 2 quarters · filed 2024-03-08 | -$760.00K derived: sum of 3 quarters · filed 2024-03-08 | -$1.57M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$1.34M derived: sum of 2 quarters · filed 2023-11-14 | -$2.15M 10-Q · filed 2023-11-14 | -$1.05M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$582.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.39M 10-Q · filed 2023-08-11 | -$287.00K derived: sum of 3 quarters · filed 2023-08-11 | -$62.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$808.00K 10-Q · filed 2023-05-05 | $295.00K derived: sum of 2 quarters · filed 2023-05-05 | $520.00K derived: sum of 3 quarters · filed 2023-05-05 | $549.00K derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.33M derived: sum of 2 quarters · filed 2023-03-31 | $1.36M derived: sum of 3 quarters · filed 2023-03-31 | $1.47M 10-K · filed 2023-03-31 |
| 2021-09-30 | $225.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $254.00K derived: sum of 2 quarters · filed 2022-11-10 | $368.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $143.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $114.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$40.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |